Authors
Latest:
How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital TherapeuticsIn the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
Latest:
Exclusivity Creates Challenges in Price, Access for Long-used MedicationsFDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern
Latest:
Health policies high on specialty radar in 2021The key trends and considerations for specialty providers navigating a changing policy landscape
Latest:
Revolutionizing Rare Disease Treatment: Embracing the Patient-Centric Transformation in Pharmaceutical Customer EngagementNavigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.
Latest:
Navigating the Biosimilars MarketplaceHow to provide effective brand engagement in this rocky yet emerging landscape.
Latest:
Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
Applying AI Case Studies in PharmaHow artificial intelligence and real-world data has not just helped predict patient behavior, but has also been successful at the point-of-care for life sciences companies.
Latest:
Medical Affairs Role in Shaping StrategyWhat the Changing Healthcare Landscape Demands of Future MA Professionals?
Latest:
Illinois Governor Signs Legislation Targeting PBM RetaliationIllinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.
Latest:
Leading in Challenging TimesIt has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.
Latest:
Coordinating payer contracts and direct-to-patient discountingAlthough controversial, patient-focused discounts can play a valuable role in managed-markets programs
Latest:
Follow-on Biologics: A Patent Litigation PerspectiveIn whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully
Latest:
Sales Force Automation's Latest Kick: Mobile and Touch-Display ApplicationsA pronounced fascination with Apple Computer's iPad is focusing sales-IT efforts on mobility and data access; meanwile, online e-detailing offerings win more acceptance
Latest:
The path to digital transformation runs through dataKey priorities: cleansed data and consolidated databases
Latest:
Risky Business: What Life Sciences Need to Know About the US Foreign Corrupt Practices Act Before an AcquisitionNearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Latest:
Safety Issues Dominate Pain MarketWhile researchers study new pain-killing pathways, the pharma industry tries drug combinations and alternative-delivery mechanisms By Angelo DePalma, PhD
Latest:
Medical marijuana looks for a place in conventional drug distributionIt's still early days in making medical marijuana--and cannabis-based pharmaceuticals--part of normal dispensing
Latest:
The Impending AMP Rule, still waiting three years laterSome state-level changes give an indication of what to prepare for
Latest:
Getting ready for Sunshine Act public dataHow to prepare for reporting and utilizing published data for business and compliance purposes
Latest:
Welcome to the new era of outsourced sales and clinical field forcesPushing your frontline into a new frontier
Latest:
For better patient data in pharma, think CUPIDA Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets
Latest:
Vaccine growth spurs device, contract-services marketsA double-digit growth rate through 2024 means boom times for drug-delivery devices and for contract manufacturing services
Latest:
The power of strategic data standardizationGlobal efforts to collect clinical data in a more standardized form will lead to more research innovation
Latest:
2014 Biopharma cold-chain forecastGlobal industry will spend $8.36 billion on cold chain logistics this year
